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Organ	transplant	recipients	(OTRs)	have	a	100-	fold	increased	risk	of	cutaneous	squa-
mous	cell	carcinoma	(cSCC).	We	prospectively	evaluated	the	association	between	β 
genus	human	papillomaviruses	(βPV)	and	keratinocyte	carcinoma	in	OTRs.	Two	OTR	
cohorts	without	cSCC	were	assembled:	cohort	1	was	transplanted	 in	2003-	2006	(n	
=	274)	 and	 cohort	 2	 was	 transplanted	 in	 1986-	2002	 (n	 =	352).	 Participants	 were	
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1  | INTRODUCTION
Cutaneous	squamous	cell	carcinoma	(cSCC)	is	the	most	common	ma-
lignancy	in	solid	organ	transplant	recipients	(OTRs),	followed	by	basal	
cell	carcinoma	(BCC).1,2	The	incidence	of	cSCC	and	BCC	increases	with	
duration of immunosuppressive therapy.1	 Important	 risk	 factors	 are	
male	sex,	 increasing	age,	fair	skin	type,	sun	exposure,	and	smoking.3 
cSCCs	are	usually	preceded	by	multiple	viral	warts	from	human	pap-
illomavirus	(HPV)	infection	and	by	actinic	keratoses,	which	also	often	
contain	HPV.3
The	 virome	 component	 of	 the	 human	 microbiome	 is	 known	 to	
play an important role in disease,4,5	and	HPV	is	particularly	prevalent	
in	the	normal	skin	virome.6,7	HPVs	are	double-	stranded	DNA	viruses	
that	are	classified	 into	5	genera	 (α, β, γ, μ, and ν).8,9 αHPVs	 (eg,	mu-
cosal	HPV	types	16	and	18)	are	responsible	for	the	development	of	
cervical	carcinoma	and	other	mucosal	SCCs,	including	anogenital	and	
oropharyngeal carcinomas.10	The	 role	of	 skin	βPVs	 in	cSCC	carcino-
genesis is controversial,9,11,12	but	evidence	for	etiologic	 involvement	
is accumulating.13-17 βPV	cause	latent,	persistent	skin	infections18 and 
were	first	discovered	in	cSCCs	from	patients	with	epidermodysplasia	
verruciformis,	a	 rare	genetic	skin	disease	characterized	by	 increased	
susceptibility	to	βPV	with	a	high	risk	of	cSCC	on	sun-	exposed	skin.9
βPVs	are	ubiquitous,	with	more	than	90%	of	people	carrying	these	
viruses	as	part	of	their	normal	skin	virome.7,19,20 Hair follicles are the 
likely	 reservoir.18 βPV-	infected	 cells	may	 have	 impaired	DNA	 repair	
and	decreased	sensitivity	to	apoptosis	induced	by	ultraviolet	radiation	
(UVR),	facilitating	escape	from	normal	cellular	defense	mechanisms.9,13 
A	substantial	body	of	epidemiologic	data	show	an	association	between	
HPV	 infection	 and	 cSCC,12,20-24	 in	 particular,	 in	 OTRs.25,26	 In	 most	
studies,	HPV	infection	has	been	determined	by	detection	of	serologic	
responses to a large series of βPV	and	sometimes	γPV	types12,21–23,25–31 
and	less	frequently	by	detecting	genomic	DNA	from	1	or	multiple	HPV	
types	in	eyebrow	hair	or	skin	scrapings.20,21,25,32-34
Case-	control	 studies	 in	both	OTR	and	 immunocompetent	popu-
lations have shown that the presence of βPV	DNA	or	antibodies	was	
associated	with	a	1.5-	to	3-	fold	increased	risk	of	cSCC.12,20–26,29,31,32 
It	was	not	possible,	however,	to	determine	whether	the	βPV	infection	
increases	risk	of	cSCC	development	or	whether	cSCC	formation	pro-
motes active proliferation of βPV.	To	our	best	knowledge,	there	is	only	
1	published	cohort	study	 in	OTRs	that	 investigated	the	 influence	of	
βPV	infection	on	the	development	of	cSCC.26	In	a	single-	center	study	
in	 445	 patients,	OTRs	who	were	 βPV	 seropositive	 around	 the	 time	
of	 transplantation	had	an	almost	3-	fold	 increased	risk	of	developing	
cSCC	during	the	22-	year	follow-	up	period.26 There are no prospective 
studies	in	which	the	associations	between	cSCC	and	both	the	number	
and	DNA	load	of	βPV	types	have	been	examined.
In	this	study,	we	present	data	from	2	prospective	multicenter	co-
hort	studies	confirming	that	the	presence	of	human	skin	βPV	infection	
is	associated	with	cSCC	development	in	OTRs.
2  | METHODS
2.1 | Participants and study design
As	 part	 of	 a	 European	 Union–funded	 fifth	 framework	 program	
(5FP)	 collaborative	 research	 grant	 (QLK2-	CT-	2002-	0117),	 the	 EPI-	
HPV-	UV-	CA	 study	 group	 collected	 data	 for	 a	 prospective35 and a 
case-	control	 study	 between	 2003	 and	 2006.3,25	 A	 description	 of	
the	inclusion	and	exclusion	criteria	is	provided	in	the	supplementary	
material	(Figures	S1A-	S1C).	Cohort	1	was	assembled	from	441	OTRs	
followed	until	death	or	cessation	of	follow-	up	in	2016.	βPV	infection	was	assessed	in	
eyebrow	hair	 by	 using	 polymerase	 chain	 reaction–based	methods.	βPV	 IgG	 serore-
sponses	were	determined	with	multiplex	serology.	A	competing	risk	model	with	de-
layed	entry	was	used	to	estimate	cumulative	incidence	of	histologically	proven	cSCC	
and the effect of βPV	by	using	a	multivariable	Cox	regression	model.	Results	are	re-
ported	as	adjusted	hazard	ratios	 (HRs).	OTRs	with	5	or	more	different	βPV	types	 in	
eyebrow	hair	had	1.7	times	the	risk	of	cSCC	vs	OTRs	with	0	to	4	different	types	(HR	
1.7,	95%	confidence	interval	1.1-	2.6).	A	similar	risk	was	seen	with	high	βPV	loads	(HR	
1.8,	95%	confidence	interval	1.2-	2.8).	No	significant	associations	were	seen	between	
serum	antibodies	and	cSCC	or	between	βPV	and	basal	cell	carcinoma.	The	diversity	and	
load of βPV	types	in	eyebrow	hair	are	associated	with	cSCC	risk	in	OTRs,	providing	evi-
dence that βPV	is	associated	with	cSCC	carcinogenesis	and	may	present	a	target	for	
future preventive strategies.
K E Y W O R D S
cancer/malignancy/neoplasia:	risk	factors,	cancer/malignancy/neoplasia:	skin	-	nonmelanoma,	
clinical	research/practice,	infection	and	infectious	agents	-	viral,	infection	and	infectious	
agents	-	viral:	papillomavirus,	organ	transplantation	in	general
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who participated in the prospective study.35	Of	these,	167	were	ex-
cluded	due	to	lack	of	sufficient	follow-	up	data,	leaving	a	final	cohort	of	
274	OTRs.	Cohort	2	was	established	from	915	OTRs	who	participated	
in	the	case-	control	study.3,25	Exclusion	of	OTRs	with	lack	of	sufficient	
follow-	up	 data	 (n	 =	242),	 an	 cSCC	diagnosed	before	 recruitment	 (n	
=	210),	 or	 transplanted	 before	 1986	 (n	 =	111)	 gave	 a	 total	 of	 352	
OTRs.	Both	cohorts	were	under	prospective	observation	until	2016.
Between	2003	 and	2006,	 relevant	 demographic	 data	 and	 infor-
mation	 about	 skin	 cancer	 risk	 factors	were	 collected.3,25,35	 Plucked	
eyebrow	 hair	 was	 collected;	 DNA	was	 extracted	 for	 detection	 and	
genotyping	 of	 25	βPV	 types	 using	 the	 skin	βPV	prototype	 research	
assay	(Labo	Bio-	medical	Products	BV,	Rijswijk,	The	Netherlands)36 and 
for	viral	 load	determination	using	quantitative	polymerase	 chain	 re-
action.32	Because	more	than	95%	of	OTRs	had	1	or	more	βPV	types	
in	their	eyebrow	hair,25	we	dichotomized	the	number	of	βPV	as	0	to	
4	and	as	5	or	more,	as	previously	published.25 High viral load was de-
fined as 1 βPV	copy	per	1	to	19	cells	and	low	load	as	1	copy	per	20	or	
more	cells.	Serum	was	collected	and	tested	for	16	βPV,	6	γPV,	4	αPV,	
2 μPV,	and	1	νPV	IgG	antibodies	with	a	multiplex	serology	technique	
based	on	glutathione	s-	transferase	capture	ELISA	in	combination	with	
fluorescent	 bead	 technology.37,38	 All	 3	 techniques	 used	 have	 been	
previously	described	in	more	detail.25,32,35-38
In	cohort	1,	eyebrow	hair	and	serum	were	collected	at	1,	3,	6,	9,	
12,	and	18	months	posttransplantation.	The	12-	month	posttransplan-
tation	time	point	was	selected	for	the	final	analyses,	because	this	time	
point	best	represented	the	βPV	DNA	measurement,	as	separate	anal-
yses	have	shown	 (Figures	S2A	and	S2B).	No	participants	had	devel-
oped	cSCC	before	this	time	point.	In	cohort	2,	DNA	and	serum	were	
collected	at	the	time	of	recruitment,	a	median	of	10	(range	2-	19)	years	
after	transplantation.	This	was	assumed	to	be	representative	of	βPV	
DNA	status	in	the	years	before	sampling	as	βPV	infection	is	character-
ized	by	a	chronic	persistent	course	with	βPV	DNA	content	in	eyebrow	
hair	being	stable	over	time.18
All	OTRs	were	routinely	seen	1	to	4	times	per	year	in	specialized	
centers	dedicated	 to	 surveillance	of	OTRs	with	 skin	 lesions.	Clinical	
information	was	collected	from	the	time	of	enrolment	between	2003	
and	2006	until	the	last	follow-	up	in	2016	and	included	the	first	histo-
logically	confirmed	cSCC	and	BCC	and	the	date	of	the	last	follow-	up	
or	death.	We	used	medical	charts,	 local	pathology	records,	and	local	
oncology	 databases	 to	 collect	 this	 information.	 Both	 cohort	 studies	
adhered	to	the	Declaration	of	Helsinki	principles,	and	the	local	medical	
ethical committees of the hospitals in the participating countries had 
approved the study design.
2.2 | Statistical analysis
Cohorts	 1	 and	 2	were	 analyzed	 separately	 and	 in	 combination.	 To	
estimate	the	independent	effect	of	risk	factors	on	the	occurrence	of	
cSCC	or	BCC,	a	Cox	model	was	used.	Second	and	subsequent	cSCCs	
or	BCCs	were	not	considered,	because	these	data	were	not	collected.	
The starting date for analysis was the day of transplantation; the end 
dates	 for	 those	 not	 diagnosed	with	 cSCC	 or	 BCC	were	 the	 end	 of	
follow-	up	 or	 death.	 Proportionality	 of	 the	 hazard	 was	 assessed	 by	
plotting	Schoenfeld	residuals	for	relevant	covariates	and	by	introduc-
ing	interactions	of	relevant	covariates	with	time	in	the	Cox	model.	A	
value of P <	.05	indicated	a	violation	of	the	proportionality	assumption.
A	competing	 risk	model	with	death	as	competing	event	and	de-
layed	entry	(also	referred	to	as	left	truncation)	was	used	to	estimate	
the	 cumulative	 incidence	 of	 first	 cSCC	 or	 BCC	 since	 transplanta-
tion.39,40	Competing	 risk	models	 take	 into	 account	 situations	where	
more	than	1	cause	of	failure	is	possible.	In	our	study,	the	2	competing	
events	were	cSCC	or	BCC	and	death,	as	patients	might	have	died	be-
forethe	occurrence	of	cSCC	or	BCC.	Delayed	entry	was	used	to	adjust	
for	the	fact	that	in	cohort	2	the	HPV	DNA	testing	and	serology	were	
not	performed	at	the	time	of	transplantation	and	that	we	had	taken	
the	12-	month	time	point	in	cohort	1.
We	had	previously	defined	a	new	variable	based	on	concordance	
of βPV	DNA	and	serology.	We	classified	OTR	according	 to	whether	
they	were	both	antibody	and	DNA	positive	for	the	same	βPV	type	as	
follows:	antibody	negative,	regardless	of	DNA	status;	antibody	posi-
tive	but	with	no	types	for	which	DNA	was	also	found;	and	antibody	
positive	with	at	least	1	type	concordant	for	DNA.25
The	final	analyses	were	adjusted	for	sex,	age,	skin	type,	and	study	
center	(study	center	being	an	important	composite	variable	represent-
ing differences in patient populations, immunosuppression regimens, 
and	sun	exposure	between	the	3	clinical	sites).	We	also	investigated	
the	other	clinical	variables,	and	none	changed	the	estimates	of	inter-
est.	These	were,	 therefore,	not	 included	 in	 the	analysis.	Analyses	of	
cohort	2	or	of	the	combined	cohorts	showed	that	adjustment	for	type	
of	immunosuppression,	type	of	organ	transplanted,	average	sun	expo-
sure,	number	of	 sunburns,	 smoking,	or	alcohol	consumption	did	not	
substantially	change	the	hazard	ratios	(HRs)	(data	not	shown).	We	did	
not	adjust	for	keratotic	skin	lesions	and	common	viral	warts,	as	these	
potentially	lie	on	the	causal	pathway	between	HPV	infection	and	cSCC	
or	BCC	and	their	inclusion	in	the	model	may	lead	to	overadjustment,	
biasing	the	result	toward	the	null.41
The	 analyses	 concerning	 the	 competing	 risk	 model	 were	 per-
formed	in	R	environment	(http://www.R-project.org)	with	the	mstate	
library.42	All	other	analyses	were	performed	with	SPSS	Statistics	 for	
Windows	version	23.0	(IBM	Corp.,	Armonk,	NY).
3  | RESULTS
The	median	and	maximum	follow-	up	times	since	transplantation	were	
9.5	and	12.4	years	 in	cohort	1	and	18.7	and	29.9	years	 in	cohort	2,	
respectively.	The	median	and	maximum	 follow-	up	 times	 since	DNA	
and	serum	sampling	did	not	differ	between	the	cohorts	and	were	9.8	
and	13.4	years,	 respectively.	At	 the	end	of	 follow-	up,	161	 (26%)	of	
626	OTRs	had	died:	52	(19%)	of	274	OTRs	in	cohort	1	and	109	(31%)	
of	352	OTRs	in	cohort	2.
The	clinical	profile	of	transplanted	patients	differed	between	co-
horts	1	and	2	(Table	1),	but	there	were	no	significant	differences	in	vi-
rologic	results	and	association	with	cSCC.	OTRs	in	cohort	1	were	more	
often	 female,	 had	 a	darker	 skin	 type,	were	 less	often	 smokers,	 and	
had	 lower	alcohol	 consumption.	Almost	all	 received	mycophenolate	
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TABLE  1 Baseline	characteristics	of	the	626	organ	transplant	recipients
Cohort 1 Cohort 2 Combined cohort
No. of patients 274 352 626
Years	of	first	transplantation 2003-	2006 1986-	2002 1986-	2006
Study	center,	n	(%)
Leiden	(The	Netherlands) 101	(36.9) 91	(25.9) 192	(30.7)
Lyon	(France) 99	(36.1) 64	(18.2) 163	(26.0)
London	(UK) 32	(11.7) 123	(34.9) 155	(24.8)
Bergamo	(Italy) 42	(15.3) 74	(21.0) 116	(18.5)
P < .001
Sex,	n	(%)
Women 98	(35.8) 96	(27.3) 194	(31.0)
Men 176	(64.2) 256	(72.7) 432	(69.0)
P = .023
Age	at	transplantation,	y
Median 56.4 50.3 52.4
IQR	(25%-	75%) 47.9-	62.6 38.4-	57.3 42.0-	58.9
P = .003
Age	at	physical	examination,	y
Median 56.4 59.8 58.2
IQR	(25%-	75%) 48.0-	62.6 52.7-	67.1 51.3-	65.7
P < .001
Skin	phototype,	n	(%)
Dark/olive 157	(57.5) 162	(46.0) 319	(51.1)
Medium 91	(33.3) 128	(36.4) 219	(35.0)
Fair 25	(9.2) 62	(17.6) 87	(13.9)
Missing values (1) P = .002
Type	of	organ,	n	(%)
Kidney 220	(80.3) 288	(81.9) 508	(81.2)
Kidney	and	pancreas 34	(12.4) 29	(8.2) 63	(10.0)
Heart 20	(7.3) 35	(9.9) 55	(8.8)
P	=	.140
Immunosuppressive	therapy,	n	(%)
Aza	in	any	combination 14	(5.1) 148	(42.0) 162	(25.9)
MMF	in	any	combination 251	(92.0) 108	(30.7) 359	(57.5)
CyA	or	Tac	without	Aza	or	MMF 8	(2.9) 96	(27.3) 104	(16.6)
Missing values (1) P < .001
Average	daily	sun	exposure,	n	(%)
1-	3	h 175	(63.9) 208	(59.1) 383	(61.2)
≥4	h 99	(36.1) 144	(40.9) 243	(38.8)
P	=	.224
Sunburns	before	the	age	of	20	y,	n	(%)
0 110	(40.4) 174	(49.4) 284	(45.5)
1-	4 108	(39.7) 123	(34.9) 231	(37.0)
≥5 54	(19.9) 55	(15.6) 109	(17.5)
Missing values (2) P	=	.073
(Continues)
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mofetil	 in	 combination	 with	 tacrolimus,	 rather	 than	 azathioprine,	
which was the main immunosuppressive drug in cohort 2. The num-
bers	of	keratotic	 lesions	and	common	viral	warts	were	higher	 in	co-
hort 2, consistent with their longer duration of immunosuppression 
(Table	1).
Table	2	 shows	 the	 cause-	specific	HRs	 for	 prognostic	 factors	 as-
sociated	 with	 cSCC	 in	 the	 2	 cohorts	 combined.	 Results	 generated	
from	 individual	 cohort	 analyses	 are	 comparable	 (Tables	 S1	 and	 S2).	
Male	sex,	increasing	age,	fair	skin	type,	and	immunosuppression	with	
azathioprine	were	 the	 strongest	 risk	 factors	 for	 cSCC.	 Because	 the	
Cohort 1 Cohort 2 Combined cohort
Smoking,	n	(%)
No 139	(50.8) 133	(38.1) 272	(43.7)
1-	19	pack-	y 76	(27.7) 136	(39.0) 212	(34.0)
≥20	pack-	y 59	(21.5) 80	(22.9) 139	(22.3)
Missing values (3) P = .003
Alcohol	consumption,	n	(%)
No 112	(57.1) 98	(27.8) 210	(38.3)
1-	19	g/d 64	(32.7) 188	(53.4) 252	(56.0)
≥20	g/d 20	(10.2) 66	(18.8) 86	(15.7)
Missing values (78) P < .001
Keratotic	skin	lesions,	n	(%)
0 205	(74.8) 111	(31.6) 316	(50.6)
1-	49 65	(23.7) 208	(59.3) 273	(43.6)
≥50 4	(1.5) 32	(9.1) 36	(5.8)
Missing values (1) P < .001
Common	viral	warts,	n	(%)
0 234	(85.7) 203	(57.8) 437	(70.0)
1-	49 33	(12.1) 103	(29.3) 136	(21.8)
≥50 6	(2.2) 45	(12.8) 51	(8.2)
Missing values (1) (1) P < .001
No. of βPV	types	in	hair
Median 4.5 4.0 4.0
IQR	(25%-	75%) 2.3-	6.8 2.0-	8.0 2.0-	7.0
P	=	.643
No. of βPV	types	in	hair
0-	4	 142	(51.8) 174	(49.4) 316	(50.5)
≥5 132	(48.2) 178	(50.6) 310	(49.5)
P	=	.552
βPV	load	(based	on	8	βPV	types)
Low	load	(1	copy	per	≥20	cells) 195	(71.2) 252	(71.6) 447	(71.4)
High	load	(1	copy	per	<20	cells) 79	(28.8) 100	(28.4) 179	(28.6)
P = .907
HPV	seropositivity
αPV 165	(60.2) 188	(53.4) 353	(56.4)
βPV 137	(50.0) 176	(50.0) 313	(50.0)
γPV 133	(48.5) 165	(46.9) 298	(47.6)
μPV 91	(33.2) 100	(28.4) 192	(30.5)
νPV 31	(11.3) 31	(8.8) 62	(9.9)
P	>	.05
The P-	values	 refer	 to	 the	 differences	 between	 cohorts	 1	 and	 2	 and	 are	 calculated	 with	 a	 χ2	 test	 (ordinal	 data)	 or	 ANOVA	 (continuous	 data).	 
Significant	P-values	are	indicated	in	bold.
Aza,	azathioprine;	CyA,	cyclosporin	A;	MMF,	mycophenolate	mofetil;	Tac,	tacrolimus.
TABLE  1  (Continued)
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TABLE  2 Possible	risk	factors	for	the	development	of	cutaneous	squamous	cell	carcinoma	in	626	organ	transplant	recipients	(combined	
cohort)
N (%)
Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
No. of patients 536 90
Study	center,	n	(%)
Leiden	(The	Netherlands) 172	(32.1) 20	(22.3) 1 1
Lyon	(France) 144	(26.9) 19	(21.1) 1.4	(0.72-	2.6) 0.93	(0.49-	1.8)
London	(UK) 126	(23.5) 29	(32.2) 1.8	(0.99-	3.2) 1.6	(0.88-	2.9)
Bergamo	(Italy) 94	(17.5) 22	(24.4) 1.5	(0.83-	2.8) 1.7	(0.90-	3.1)
Sex,	n	(%)
Women 176	(32.8) 18	(20.0) 1 1
Men 360	(67.2) 72	(80.0) 1.7 (1.01-2.7) 2.0 (1.2-3.5)
Age	at	transplantation	per	10	y
Median 51.9 54.8
IQR	(25%-	75%) 41.9-	58.8 46.8-	61.8 1.8 (1.4-2.1) 2.1 (1.7-2.6)
Age	at	physical	examination	per	10	y
Median 57.8 64.5
IQR	(25%-	75%) 51.2-	65.43 58.1-	67.6 1.9 (1.5-2.3) 2.1 (1.7-2.7)
Skin	phototype,	n	(%)
Dark/olive 287	(53.6) 32	(35.6) 1 1
Medium 184	(34.4) 35	(38.9) 1.6	(0.99-	2.6) 1.9 (1.2-3.2)
Fair 64	(12.0) 23	(25.5) 3.3 (1.9-5.6) 3.9 (2.2-7.0)
Missing values (1)
Type	of	organ,	n	(%)
Kidney 434	(81.0) 74	(82.2) 1
Kidney	and	pancreas 59	(11.0) 4	(4.4) 0.45	(0.16-	1.2) 0.81	(0.28-	2.4)
Heart 43	(8.0) 12	(13.4) 1.8	(0.97-	3.3) 1.1	(0.53-	2.2)
Immunosuppressive	therapy,	n	(%)
Aza	in	any	combination 108	(20.2) 54	(60.0) 1 1
MMF	in	any	combination 334	(62.4) 25	(27.8) 0.22 (0.13-0.38) 0.28 (0.15-0.50)
CyA	or	Tac	without	Aza	or	MMF 93	(17.4) 11	(12.2) 0.33 (0.17-0.64) 0.25 (0.13-0.50)
Missing values (1)
Average	daily	sun	exposure,	n	(%)
1-	3	h 335	(62.5) 48	(53.3) 1 1
≥4	h 201	(37.5) 42	(46.7) 1.4	(0.90-	2.1) 1.1	(0.71-	1.7)
Sunburns	before	the	age	of	20	y,	n	(%)
0 243	(45.4) 41	(46.1) 1 1
1-	4 196	(36.7) 35	(39.3) 1.1	(0.68-	1.7) 0.91	(0.56-	1.	5)
≥5 96	(17.9) 13	(14.6) 0.92	(0.49-	1.7) 0.66	(0.33-	1.3)
Missing values (1) (1)
Smoking,	n	(%)
No 240	(44.9) 32	(36.0) 1 1
1-	19	pack-	y 182	(34.1) 30	(33.7) 1.1	(0.69-	1.9) 0.94	(0.56-	1.6)
≥20	pack-	y 112	(21.0) 27	(30.3) 1.9 (1.1-3.2) 1.1	(0.65-	1.9)
Missing values (2) (1)
(Continues)
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majority	 (>80%)	 of	 both	 cohorts	 were	 kidney	 transplant	 recipients,	
we	had	 insufficient	 statistical	 power	 to	 assess	differences	 in	 risk	of	
cSCC	according	to	type	of	organ	transplant	received.	As	we	have	re-
ported earlier,3	the	number	of	keratotic	skin	lesions	and	common	viral	
warts	was	strongly	associated	with	the	development	of	cSCC,	with	an	
adjusted	HR	of	4.7	(95%	confidence	interval	[CI]	2.0-	10.9)	for	OTRs	
with	50	or	more	lesions	compared	with	those	OTRs	with	fewer	lesions.	
After	adjustment,	sun	exposure,	painful	sunburns,	and	smoking	were	
not	associated	with	cSCC	in	the	combined	cohort	(Table	2).
The	 number	 of	 βPV	 types	 in	 eyebrow	 hair,	 βPV	DNA	 load,	 and	
serologic	 responses	 to	HPV	did	not	 significantly	differ	between	 the	
2	cohorts	 (Table	1).	Figure	1	 shows	a	higher	overall	 cumulative	 inci-
dence	of	cSCC	 in	OTRs	 infected	with	multiple	 (≥5)	HPV	types	mea-
sured 12 months posttransplantation in cohort 1 and after a median 
of	10	years	posttransplantation	in	cohort	2	compared	with	OTR	with	
fewer βPV	types	or	noninfected	OTRs	(Figure	1A).	The	cumulative	inci-
dence	of	cSCC	for	the	separate	cohorts	is	provided	in	Figures	S3A	and	
S3B.	Table	3	reports	the	association	between	presence	of	βPV	DNA	
in	eyebrow	hair	and	subsequent	development	of	cSCC.	The	combined	
adjusted	HR	was	1.7	 (95%	CI	1.1-	2.6).	More	detailed	 information	 is	
provided	in	the	Tables	S3-	S5.
High βPV	load	was	also	associated	with	a	significantly	higher	cu-
mulative	incidence	of	cSCC	compared	with	a	low	load	or	absent	βPV	
types	 (Figure	1B	and	Table	3).	 In	 the	combined	cohort,	 the	adjusted	
HR	was	1.8	(95%	CI	1.2-	2.8).	The	βPV	load	risk	factor	in	cohort	1	was	
probably	driving	the	HRs	in	the	combined	analyses.
HPV	seropositivity	at	the	time	of	sampling	was	not	associated	with	
cSCC	risk	(Figures	1C	and	1D	and	Table	3).	The	association	was	stronger	
but	still	not	significant	 for	concordant	serologic	 responses	 (Figure	1D	
and	Table	3).	We	observed	a	weak	association	between	γPV	seroposi-
tivity	and	cSCC	(Table	3)	but	no	association	with	αPV,	μPV,	and	νPV	se-
ropositivity	(Tables	S3-	S5).	We	examined	possible	heterogeneity	of	βPV	
effects	between	cohorts	1	and	2,	but	this	was	not	the	case	in	the	univar-
iate	and	adjusted	analyses	for	any	of	the	variables	in	Table	3.	We	were	
unable	to	assess	the	 influence	of	type	of	organ	transplanted	because	
our	study	populations	were	mostly	kidney	transplant	recipients.	There	
was	no	evidence	of	violation	of	the	proportional	hazard	assumption.
Data	 on	 individual	HPV	 types	 suggested	 that	 βPV	 of	 species	 1,	
specifically	HPV	types	5,	8,	20,	21,	and	36,	are	those	most	likely	to	be	
involved	 in	 cutaneous	 squamous	 carcinogenesis,	with	possible	 roles	
for	HPV76	(species	3)	and	HPV92	(species	4)	(Table	S6).	The	increased	
risk	of	skin	cancer	was	specific	 for	cSCC;	 there	were	no	statistically	
significant	associations	between	HPV	infection	and	the	development	
of	BCC	(Table	S7).
4  | DISCUSSION
In	this	observational	hospital-	based	study	of	2	OTR	cohorts	with	a	fol-
low-	up	period	after	HPV	sampling	of	longer	than	10	years,	we	found	
that the diversity and load of infecting βPV	types	were	associated	with	
an	approximately	doubled	risk	of	cSCC.	Our	results	were	robust	after	
adjustment for multiple potential confounders. This level of increased 
risk	 is	equivalent	 to	 that	associated	with	other	well-	established	 risk	
factors	such	as	skin	phototype3 and points to an important role for the 
skin	virome	and	specifically	HPV	in	the	pathogenesis	of	cSCC.
HPV	 constitute	 an	 important	 part	 of	 the	 normal	 human	 skin	 vi-
rome.6,7,19,20	There	is	strong	evidence	from	laboratory	studies	to	suggest	
N (%)
Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
Alcohol	consumption,	n	(%)
No 190	(41.0) 20	(23.5) 1 1
1-	19	g/d 207	(44.7) 45	(52.9) 1.6	(0.97-	2.8) 1.4	(0.83-	2.5)
≥20	g/d 66	(14.3) 20	(23.6) 2.5 (1.3-4.6) 1.8	(0.93-	3.5)
Missing values (73) (5)
Keratotic	skin	lesions,	n	(%)
0 299	(55.9) 17	(18.9) 1 1
1-	49 213	(39.8) 60	(66.7) 4.1 (2.3-7.1) 3.1 (1.7-5. 5)
≥50 23	(4.3) 13	(14.4) 8.0 (3.8-16.6) 4.7 (2.0-10.9)
Missing values (1)
Common	viral	warts,	n	(%)
0 387	(72.5) 50	(55.6) 1 1
1-	49 113	(21.1) 23	(25.6) 1.3	(0.80-	2.2) 1.3	(0.77-	2.2)
≥50 34	(6.4) 17	(18.8) 2.3 (1.3-4.1) 2.5 (1.3-5.0)
Missing values (2)
All	hazard	ratios	(HRs)	are	calculated	using	delayed	entry	and	adjusting	for	competitive	risk	of	death.	Significant	HRs	are	indicated	in	bold.
Aza,	azathioprine;	CyA,	cyclosporin	A;	MMF,	mycophenolate	mofetil;	SCC,	squamous	cell	carcinoma;	Tac,	tacrolimus.
aThe	adjusted	HRs	are	calculated	with	the	factor	of	interest	and	sex,	age	at	physical	examination,	skin	type,	and	study	center	included	in	the	model.
TABLE  2  (Continued)
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F IGURE  1 Cumulative	incidence	of	cutaneous	squamous	cell	carcinoma	in	organ-	transplant	recipients	with	5	and	more	HPV	types	in	
eyebrow	hair	measured	12	mo	post-	transplant	in	cohort	1	and	after	a	median	of	10	years	post-	transplant	in	cohort	2	(red	line)	compared	with	
transplant	recipients	with	0-	4	HPV	types	(black	line)	(Panel	A);	with	a	high	βPV	load	in	plucked	eyebrow	hair	(red	line)	compared	with	transplant	
recipients	with	a	low	load	or	absence	of	these	8	specific	βPV	types	(black	line)	(Panel	B);	with	a	positive	serologic	response	to	βPV	(red	line)	
compared	with	transplant	recipients	without	a	positive	response	(black	line)	(Panel	C);	with	a	positive	serologic	response	to	βPV	in	combination	
with the same βPV	type(s)	in	the	eyebrow	hair	(green	line),	and	with	a	positive	serologic	response	to	βPV	in	combination	with	different	βPV	types	
in	the	eyebrow	hair	(red	line)	compared	with	transplant	recipients	without	a	positive	response	(black	line)	(Panel	D).	The	curves	are	adjusted	for	
competitive	risk	of	death	and	for	delayed	inclusion	of	the	patients.	Due	to	the	delayed	inclusion,	the	numbers	of	patients	at	risk	initially	increase	
with	time	before	they	decrease
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     |  9BOUWES BAVINCK Et Al.
that	HPV	plays	a	role	in	cSCC	carcinogenesis,	principally	through	syn-
ergy	with	UVR.13-15	In	normal	cells,	UVR	upregulates	cellular	defense	
processes leading to p53	activation,	cell	cycle	arrest,	apoptosis,	or	DNA	
repair.	Several	βPV	types	 (eg,	HPV5,	HPV8,	HPV38,	and	HPV49)	de-
regulate	these	crucial	cellular	regulatory	pathways	by	targeting	multi-
ple	transcription	factors	and/or	transcriptional	regulators,	resulting	in	
infected	 cells	 that	 are	 highly	 susceptible	 to	 chromosomal	 instability	
and	malignant	transformation	by	UVR.9,15,43	Synergy	between	βPV	and	
UVR	has	also	been	documented	in	animal	models.	In	transgenic	mice	
expressing	 the	HPV8	early	 region	or	E6 gene alone, a single dose of 
UVR	rapidly	promoted	papillomas	and	cSCC	formation,16	and	in	HPV38	
E6/E7	 transgenic	mice,	UVR	also	 induced	the	development	of	actinic	
keratoses	and	cSCC.17 Certain βPV	types	also	appear	to	have	enhanced	
replication	in	the	context	of	host	immunosuppression,	likely	accompa-
nied	by	increased	oncogene	expression	and	oncogenic	activity.44
Previous	epidemiologic	studies	investigating	the	association	between	
βPV	and	cutaneous	squamous	carcinogenesis	have	generated	inconsis-
tent findings.9,11,12	One	of	the	challenges	is	the	diversity	of	recognized	
HPV	types	within	the	normal	skin	virome.33,34	More	than	200	HPV	types	
have	been	identified,	and	the	number	of	putative	new	types	is	increas-
ing.33,34,45	We	tested	for	only	a	subset	of	HPV	types.	Our	polymerase	
chain	reaction–based	βPV	DNA	detection	technique	was	state-	of-	the-	
art	when	we	initiated	this	study	and	remains	a	reliable	and	reproducible	
method.	It	is	possible,	however,	that	the	true	association	between	βPV	
infection	and	cSCC	 is	even	stronger,	 as	we	may	have	 failed	 to	detect	
additional	relevant	HPV	infections.	We	also	observed	that	seropositivity	
to γPV	was	associated	with	subsequent	cSCC,	supporting	recent	findings	
that γPV	type	HPV197	is	commonly	present	in	skin	tumors34 and that its 
E6 and E7 proteins interact with a set of cellular proteins similar to those 
encoded	by	genital	HPVs	linked	to	human	carcinogenesis.45
Another	limitation	of	this	study	was	the	lack	of	follow-	up	data	in	
Berlin	and	Verona.	While	this	decreased	the	power	of	the	study,	we	
believe	that	it	is	unlikely	to	have	introduced	bias	because	all	patients	in	
these	2	centers	were	excluded,	independent	of	their	medical	history.	
Although	cohort	1	was	ideally	designed	for	analysis	of	the	involvement	
of	HPV	in	cSCC	development,	we	were	hampered	by	the	low	number	
of events during the first 10 years after transplantation. Therefore, 
cohorts	 1	 and	 2	 were	 combined,	 which	 in	 the	 crude	 associations	
between	the	presence,	number,	and	load	of	βPV	DNA	with	the	later	
development	of	 cSCC	appeared	 similar.	There	were	also	differences	
between	the	2	cohorts.	In	recent	years,	older	patients	were	more	fre-
quently	transplanted,	the	immunosuppressive	regimen	changed,	and	a	
larger	proportion	of	patients	with	a	darker	skin	phototype	were	trans-
planted, especially in Leiden and London.
Other	 potential	 limitations	 of	 this	 study	 are	missing	 data	 in	 the	
clinical	 characteristics	 included	 in	 the	 multivariable	 analyses.	 Of	
TABLE  3 Risk	of	cutaneous	squamous	cell	carcinoma	in	organ	transplant	recipients	with	human	papillomavirus	infection	according	to	the	
presence of βPV	DNA	and/or	serologic	response	to	βPV
No. of squamous cell carcinoma 
cases/total populationa
Cohort 1 
14/274
Cohort 2 
76/352
Both cohorts combined 
90/626
Risk factors
Cause- specific 
univariate HRb
Cause- specific 
univariate HR Adjusted HRc
Cause- specific 
univariate HR Adjusted HRc
βPV	DNA	(based	on	25	βPV	types)
0-	4	types 1 1 1 1 1
≥5 2.6	(0.82-	8.3) 1.8 (1.1-2.8) 1.6	(0.998-	2.7) 1.9 (1.2-2.9) 1.7 (1.1-2.6)
βPV	load	(based	on	8	βPV	types)
Low	load	(1	copy	per	≥20	cells) 1 1 1 1 1
High	load	(1	copy	per	<20	cells) 4.6 (1.5-13.8) 1.8 (1.1-2.8) 1.5	(0.92-	2.4) 2.1 (1.4-3.1) 1.8 (1.2-2.8)
βPV	serology	(based	on	16	βPV	types)
Seronegative 1 1 1 1 1
Seropositive 1.0	(0.36-	2.9) 1.6 (1.02-2.6) 1.5	(0.90-	2.4) 1.5	(0.97-	2.3) 1.4	(0.90-	2.1)
Combination	βPV	DNA	and	serology
Seronegative	irrespective	DNA 1 1 1 1 1
Seropositive	without	concordant	
DNA
0.98	(0.25-	3.9) 1.2	(0.69-	2.2) 1.2	(0.66-	2.2) 1.2	(0.69-	2.0) 1.2	(0.71-	2.1)
Seropositive	with	concordant	DNA 1.1	(0.31-	3.6) 2.0 (1.2-3.3) 1.7 (1.002-3.0) 1.8 (1.1-2.9) 1.5	(0.93-	2.5)
γPV	serology	(based	on	6	γPV	types)
Seronegative 1 1 1 1 1
Seropositive 1.1	(0.38-	3.1) 1.5	(0.93-	2.3) 1.7 (1.1-2.8) 1.4	(0.91-	2.1) 1.6 (1.01-2.4)
All	hazard	ratios	(HRs)	are	calculated	using	delayed	entry	and	adjusting	for	competitive	risk	of	death.	Significant	HRs	are	indicated	in	bold.
aThe	detailed	numbers	of	squamous	cell	carcinoma	per	cohort	and	per	exposure	are	provided	in	the	supplementary	material	(Tables	S3-	S5).
bAdjusted	HRs	are	not	available	for	cohort	1	because	of	low	number	of	events.
cThe	HRs	are	adjusted	for	sex,	age	at	physical	examination,	skin	type,	and	study	center.
10  |     BOUWES BAVINCK Et Al.
particular	concern	 is	 the	28%	missing	data	for	alcohol	consumption,	
but	we	found	no	evidence	that	adjusting	for	alcohol	in	those	with	com-
plete information made any difference to the estimates of association 
between	HPV	and	cSCC.	We	have	no	good	explanation	why	we	did	
not find a statistically significant association with βPV	serology.	We	
have	shown	a	40%	increased	risk	of	cSCC	overall	in	seropositive	OTRs	
but	had	to	exclude	a	substantial	number	of	patients	because	of	miss-
ing	data,	decreasing	the	power	of	our	study,	which	may	be	a	possible	
explanation	of	our	failure	to	show	a	statistically	significant	association	
between	βPV	serology	and	cSCC.
This cohort study provides evidence that infection with βPV	 is	
associated	with	 the	development	of	cSCC.	βPV	vaccines	are	now	 in	
development, and our data provide a rationale for routine pretrans-
plantation	 screening	 of	 the	 skin	 virome	 for	 βPV	 content	 and	 βPV	
vaccination	 of	 high-	risk	 individuals	 as	 a	 possible	 future	 strategy	 for	
reducing	the	burden	of	posttransplantation	cSCC.
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